Dr. Tong Zhang is a Managing Director, C-Bridge Capital. In this role, he is responsible for Healthcare PE focusing on growth stage opportunities in US and China. Prior to C-Bridge, he was the VP, head of Corporate BD at WuXi AppTec., responsible for strategic partnership and M&A to strengthen WuXi’s comprehensive platform supporting R&D and manufacturing for pharmaceutical, medical device, cell and gene therapy, diagnostics and genomics products and services. Prior to WuXi as head of Business Development for MSD China, he led BD activities for including M&A, investment and commercial partnership. Previously Tong was pan-regional lead for Emerging Market business development team at Merck & Co., with responsibilities for sourcing and executing BD activities across emerging markets and an emphasis on China. Tong was head of Business Development at EKR Therapeutics, a VC-backed specialty pharmaceutical company in the US, where he led several acquisition, licensing and collaboration deals, valued at over $150M. Tong also had investment experience as a Director at ESP Equity Partners, a private investment company focused on biopharmaceutical industry in the US and China, and as an equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health, leading strategy consulting firms in the biopharmaceutical industry. Tong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.